KDM1A and plasma cell myeloma: Regardless, our results substantiate that such targeting can offer superior anti-tumor efficacy in malignancies that are especially sensitive to LSD1 inhibitors such as erythroleukaemia, acute myeloid leukemia as well as in other cancers such as multiple myeloma.